Skip to main navigation Skip to search Skip to main content

TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases

  • Rachel A. Freedman
  • , Rebecca S. Gelman
  • , Carey K. Anders
  • , Michelle E. Melisko
  • , Heather A. Parsons
  • , Anne M. Cropp
  • , Kelly Silvestri
  • , Christine M. Cotter
  • , Kathryn P. Componeschi
  • , Juan M. Marte
  • , Roisin M. Connolly
  • , Beverly Moy
  • , Catherine H. Van Poznak
  • , Kimberly L. Blackwell
  • , Shannon L. Puhalla
  • , Rachel C. Jankowitz
  • , Karen L. Smith
  • , Nuhad Ibrahim
  • , Timothy J. Moynihan
  • , Ciara C. O'Sullivan
    • Julie Nangia, Polly Niravath, Nadine Tung, Paula R. Pohlmann, Robyn Burns, Mothaffar F. Rimawi, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Nancy U. Lin

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience